<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738852</url>
  </required_header>
  <id_info>
    <org_study_id>2000023189</org_study_id>
    <nct_id>NCT03738852</nct_id>
  </id_info>
  <brief_title>Mechanisms for Restoration of Hypoglycemia Awareness</brief_title>
  <official_title>Mechanisms for Restoration of Hypoglycemia Awareness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess if using the hypoglycemic clamp and functional magnetic resonance imaging (fMRI)
      scanning in hypoglycemia unaware and aware T1DM patients and healthy controls have showed
      distinct differences in patterns of brain responses. In particular, T1DM patients who are
      aware of hypoglycemia (T1DM-Aware) have greater activity in sensory integration brain regions
      (e.g. parietal lobe and caudate nucleus) in response to hypoglycemia, whereas hypoglycemia
      unaware T1DM patients (T1DM-Unaware) show no detectable changes in brain reward regions
      during hypoglycemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the following: 1) if these differences are driven purely by recurrent hypoglycemia
      or by other closely linked factors (e.g. glycemic variability); 2) the molecular and
      metabolic mechanisms by which unawareness leads to the suppression of central nervous system
      (CNS) activity in the context of hypoglycemia; and 3) whether hypoglycemia avoidance using
      closed loop systems restores central nervous system (CNS) activation and metabolism toward
      normal levels and offers a therapeutic approach to more effectively combat neurocognitive
      dysfunction associated with intensive treatment of T1DM patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Brain glucose levels</measure>
    <time_frame>3 months</time_frame>
    <description>Brain glucose will be lower and brain activation higher in those receiving closed loop Rx.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>type 1 diabetes mellitus user aware subjects 3 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MiniMed 670G Insulin Pump in Closed Loop/Auto Mode for 3 months duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>type 1 diabetes mellitus user aware subjects 4 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MiniMed 670G Insulin Pump in Closed Loop/Auto Mode for 4 weeks duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>type 1 diabetes mellitus user aware subject standard insulin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Continue with subject's standard insulin regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>insulin pump closed loop</intervention_name>
    <description>MiniMed 670G Insulin Pump in Closed Loop/Auto Mode</description>
    <arm_group_label>type 1 diabetes mellitus user aware subjects 3 months</arm_group_label>
    <arm_group_label>type 1 diabetes mellitus user aware subjects 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>standard insulin regimen</description>
    <arm_group_label>type 1 diabetes mellitus user aware subject standard insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages &gt; 18 years

          -  Healthy, non-diabetic control or T1DM

          -  BMI &gt; 18.0

        Exclusion Criteria:

          -  Use of MiniMed 670G in Closed Loop Mode or use of t:slim X2 with Control-IQ prior to
             the start of Aim 3

          -  Creatinine &gt; 1.5 mg/dL

          -  Hct &lt; 35% for females, &lt; 39% for males

          -  ALT &gt; 2.5 X ULN

          -  untreated thyroid disease

          -  uncontrolled hypertension

          -  neurologic disorders

          -  untreated depression or change in antidepressant regimen in last 3 months

          -  use of any anxiolytic medications (benzodiazepine) or antipsychotic medications

          -  greater than 5% change in weight in last 3 months

          -  malignancy

          -  current or recent steroid use in last 3 months

          -  illicit drug use

          -  significant complications related to diabetes (peripheral neuropathy, proliferative
             retinopathy)

          -  inability to enter MRI (per standard MRI safety guidelines)

          -  for women: pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Hwang, Hwang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janice Hwang, MD</last_name>
    <phone>203-785-6222</phone>
    <email>janice.hwang@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigation (YCCI) Church Street Research Unit (CSRU)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

